302 related articles for article (PubMed ID: 20124443)
1. Why doesn't imatinib cure chronic myeloid leukemia?
Redner RL
Oncologist; 2010; 15(2):182-6. PubMed ID: 20124443
[TBL] [Abstract][Full Text] [Related]
2. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
4. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
[TBL] [Abstract][Full Text] [Related]
5. Combining nilotinib and imatinib improves the outcome of imatinib-resistant blast phase CML.
Zhu GR; Ji O; Ji JM; Zhang YC; Wu Y; Yu H; Jiang PJ; Shen Q
Acta Haematol; 2012; 127(3):152-5. PubMed ID: 22286512
[TBL] [Abstract][Full Text] [Related]
6. Targeted chronic myeloid leukemia therapy: Seeking a cure.
Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate in the treatment of chronic myelogenous leukemia.
Borthakur G; Cortes JE
Int J Hematol; 2004 Jun; 79(5):411-9. PubMed ID: 15239390
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms and implications of imatinib resistance mutations in BCR-ABL.
Nardi V; Azam M; Daley GQ
Curr Opin Hematol; 2004 Jan; 11(1):35-43. PubMed ID: 14676625
[TBL] [Abstract][Full Text] [Related]
9. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
[TBL] [Abstract][Full Text] [Related]
10. Is telomerase a player in chronic phase chronic myeloid leukemia, disease progression and imatinib resistance?
White DL
Leuk Lymphoma; 2008 Jun; 49(6):1022-3. PubMed ID: 18452091
[No Abstract] [Full Text] [Related]
11. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
Guilhot F; Apperley J; Kim DW; Bullorsky EO; Baccarani M; Roboz GJ; Amadori S; de Souza CA; Lipton JH; Hochhaus A; Heim D; Larson RA; Branford S; Muller MC; Agarwal P; Gollerkeri A; Talpaz M
Blood; 2007 May; 109(10):4143-50. PubMed ID: 17264298
[TBL] [Abstract][Full Text] [Related]
12. Resistance to imatinib in chronic myelogenous leukemia: mechanisms and clinical implications.
La Rosée P; Hochhaus A
Curr Hematol Malig Rep; 2008 Apr; 3(2):72-9. PubMed ID: 20425450
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations.
San José-Enériz E; Román-Gómez J; Jiménez-Velasco A; Garate L; Martin V; Cordeu L; Vilas-Zornoza A; Rodríguez-Otero P; Calasanz MJ; Prósper F; Agirre X
Mol Cancer; 2009 Sep; 8():69. PubMed ID: 19723306
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate in the treatment of chronic myeloid leukaemia.
Druker BJ
Expert Opin Pharmacother; 2003 Jun; 4(6):963-71. PubMed ID: 12783592
[TBL] [Abstract][Full Text] [Related]
15. Carboxyamidotriazole-orotate inhibits the growth of imatinib-resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis.
Corrado C; Flugy AM; Taverna S; Raimondo S; Guggino G; Karmali R; De Leo G; Alessandro R
PLoS One; 2012; 7(8):e42310. PubMed ID: 22879938
[TBL] [Abstract][Full Text] [Related]
16. Resistance to imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problem.
Breccia M; Alimena G
Cardiovasc Hematol Disord Drug Targets; 2009 Mar; 9(1):21-8. PubMed ID: 19275574
[TBL] [Abstract][Full Text] [Related]
17. Imatinib: a review of its use in chronic myeloid leukaemia.
Moen MD; McKeage K; Plosker GL; Siddiqui MA
Drugs; 2007; 67(2):299-320. PubMed ID: 17284091
[TBL] [Abstract][Full Text] [Related]
18. Endoplasmic reticulum stress-mediated apoptosis in imatinib-resistant leukemic K562-r cells triggered by AMN107 combined with arsenic trioxide.
Xia Y; Fang H; Zhang J; Du Y
Exp Biol Med (Maywood); 2013 Aug; 238(8):932-42. PubMed ID: 23883479
[TBL] [Abstract][Full Text] [Related]
19. Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia.
Giles FJ; Cortes JE; Kantarjian HM
Curr Mol Med; 2005 Nov; 5(7):615-23. PubMed ID: 16305488
[TBL] [Abstract][Full Text] [Related]
20. Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib.
Mayerhofer M; Gleixner KV; Mayerhofer J; Hoermann G; Jaeger E; Aichberger KJ; Ott RG; Greish K; Nakamura H; Derdak S; Samorapoompichit P; Pickl WF; Sexl V; Esterbauer H; Schwarzinger I; Sillaber C; Maeda H; Valent P
Blood; 2008 Feb; 111(4):2200-10. PubMed ID: 18024796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
